Company performance
Current Price
as of Jan 17, 2025$6.57
P/E Ratio
N/A
Market Cap
$37.84M
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Metrics
Overview
- HQThousand Oaks, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerATRA
- Price$6.57-16.09%
Trading Information
- Market cap$37.84M
- Float74.88%
- Average Daily Volume (1m)340,815
- Average Daily Volume (3m)173,933
- EPS-$25.66
Company
- Revenue$100.44M
- Rev growth (1yr)1,779.79%
- Net income-$21.91M
- Gross margin81.08%
- EBITDA margin-51.07%
- EBITDA-$20.53M
- EV$81.44M
- EV/Revenue0.81
- P/EN/A
- P/S0.49
- P/BN/A
Documents
SEC Filings
Factset Street Account